Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
Patients with relapsed/refractory (R/R) T-cell lymphoma (TCL) have limited treatment options.
Chimeric antigen receptor (CAR) T cell therapy has been challenging in these patients because of the state of their T cells.
CTX130 is an allogeneic (from a healthy donor) CAR T cell therapy targeting CD70 on cancerous T cells, offering a potential cell therapy option for these patients. In a Phase I study led by Swaminathan P. Iyer, M.D., researchers evaluated the safety and efficacy of CTX130 in 17 patients with relapsed/refractory (R/R) TCL.
At the two highest dose levels, the overall response rate was 71% in seven patients, including two complete responses (29%). Responses were seen both in patients with peripheral TCL (PTCL) and transformed cutaneous TCL (CTCL).
The therapy had an acceptable safety profile, with no instances of graft versus host disease and no Grade 3 or higher cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome.
The early results suggest CTX130 is safe and, as a first-in-class allogeneic CAR T cell therapy, offers clinically meaningful benefits for patients with advanced TCL. Iyer will present updated findings on June 11.
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.